4 Medical Device M&A Deals I’d Like To See
Abbott Laboratories’ acquisition of St. Jude Medical for $25 billion in a bid to create a cardiovascular giant made sense to some, but others questioned the wisdom of the deal.
Buying another company with a slower sales growth rate for $25 billion doesn’t sound like a recipe to please shareholders. Neither does financing the deal by issuing additional stock, significantly reducing shareholder repurchases and moderating growth of the dividend.
Buying another company with a slower sales growth rate for $25 billion doesn’t sound like a recipe to please shareholders. Neither does financing the deal by issuing additional stock, significantly reducing shareholder repurchases and moderating growth of the dividend.